Literature DB >> 6461606

Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

H H Gadebusch, D L Shungu, E Weinberg, S K Chung.   

Abstract

425 randomly selected, fresh clinical isolates were tested for susceptibility to norfloxacin and other orally absorbed agents, i.e. amoxicillin, ampicillin, carbenicillin (available commercially as the indanyl ester), cefaclor, cinoxacin, erythromycin, nalidixic acid, penicillin G, tetracycline, trimethoprim and co-trimoxazole. The results have shown norfloxacin to be the most potent agent in vitro against representative members of the family Enterobacteriaceae, Staphylococcus aureus, Pseudomanas aeruginosa, Acinetobacter spp., Neisseria gonorrhoeae and Haemophilus influenzae. Ninety percent of the isolates in these groups of bacteria were inhibited by less than 1 mg/l, 2 mg/l, 8 mg/l, 32 mg/l, 0.06 mg/l and 0.25 mg/l of norfloxacin, respectively. Although norfloxacin inhibited most streptococci and Ureaplasma at a concentration of 8 mg/l or less, penicillin G proved to be the most active against Streptococcus pygenes and Streptococcus pneumoniae; trimethoprim was the most active against Streptococcus faecalis, and tetracycline the most active against Ureaplasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6461606     DOI: 10.1007/bf01640837

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  4 in total

Review 1.  Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.

Authors:  S R Bushby
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

2.  Susceptibility testing to trimethoprim alone and combined with sulphonamides.

Authors:  K Dornbusch; L Gezelius
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

3.  Serological typing of Ureaplasma urealyticum isolates from urethritis patients by an agar growth inhibition method.

Authors:  M C Shepard; C D Lunceford
Journal:  J Clin Microbiol       Date:  1978-11       Impact factor: 5.948

4.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

  4 in total
  20 in total

1.  In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  C Simon; U Lindner
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

2.  Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria.

Authors:  S J Wood; S Shadomy
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

3.  Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.

Authors:  D L Shungu; V Tutlane; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

4.  Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.

Authors:  S M Qadri; S Johnson
Journal:  J Natl Med Assoc       Date:  1989-04       Impact factor: 1.798

5.  In-vitro activity of lomefloxacin (SC-47111) and other quinolones.

Authors:  Z M Sun; J P Maskell; S C Sehgal; J D Williams
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

6.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

7.  In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  P B Fernandes; D T Chu; R R Bower; K P Jarvis; N R Ramer; N Shipkowitz
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

8.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 9.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

10.  Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.

Authors:  D A Haase; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.